| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1305 | |
| Phytochemical name or plant extracts | DLBS1425 | |
| PMID | 25158670 | |
| Literature evidence | Taken together, results of the present study suggest that DLBS1425 is safe when used as adjuvant therapy for breast cancer and may be even protective against cardiac cellular damage produced by chemotherapeutic regimen. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | DLBS1425 is a bioactive compound extracted from Phaleria macrocarpa | |
| Source of phytochemicals or plant Extracts | Phaleria macrocarpa | |
| Geographical availability | New Guinea | |
| Plant parts | Fruits | |
| Other cancers | Breast cancer | |
| Target gene or protein | BAD, Bax | |
| Gene or Protein evidence | It induced pro-apoptotic genes including BAX and BAD and consequently induces cellular death signal by caspase-9 activation. | |
| Target pathways | Anti proliferative and proapoptosis effects via eicosanoid pathway, Induction of cellular apoptosis in human breast cancer via down-regulation of PI3-kinase/AKT pathway. | |
| IC50 | NA | |
| Potency | Treatment with DLBS1425 alone up to a dose equivalent to as high as 300 mg three times daily in human had no hazardous consequences on the heart, hematological feature, as well as general safety. In the cardiovascular cells, DLBS1425 in the presence of FAC regimen (one-eight of the initial dose) gave protection to the cardiac muscle cells as well as other hematological features. | |
| Cell line/ mice model | MDA-MB-231, MCF-7 | |
| Additional information | In the cardiovascular cells, DLBS1425 in the presence of FAC regimen (one-eight of the initial dose) gave protection to the cardiac muscle cells as well as other hematological features. | |
| PubChem ID | 144221051 | |
| Additional PMIDs | 20734918 20703095 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:832478-1 | |
| Safety | NA |